Behrad Derakhshan, Ph.D.

Behrad Derakhshan, Ph.D., Chief Business Officer

Behrad Derakhshan, Ph.D. has served as Chief Business Officer since September 2020 and leads Edgewise’s efforts in strategic planning, business development, capital formation, investor relations, commercial and competitive intelligence. Prior to joining Edgewise, Dr. Derakhshan was Chief Business Officer at VectivBio after having served as the Head of Business Development at Therachon, until its acquisition by Pfizer Inc. in 2019 for $810 million. Prior to Therachon, Dr. Derakhshan was responsible for Business Development and Strategic Evaluation at Alexion. Earlier in his career, Dr. Derakhshan worked in management consulting with a focus on rare disease drug development. Dr. Derakhshan serves on the board of Innoskel, a private biotechnology company developing therapies for rare bone diseases. Dr. Derakhshan conducted his postdoctoral training at the Yale School of Medicine and received his Ph.D. in biochemistry from a joint program between Weill Cornell Medicine, New York and the University of Surrey, UK.